a day ago
National Cancer Malaysia Partners Biocon In Offering Affordable Cancer Care For The Underserved
Biocon Biologics Limited, has partnered with the National Cancer Society of Malaysia to launch a Patient Assistance Program (PAP) in Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia.
The partnership will see Biocon Biologics providing quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance
cancer care accessibility and affordability in Malaysia.
The program will start with providing Trastuzumab to cancer patients facing treatment delays due to budget constraints.
Ratish Trehan, Head of Commercial – Emerging Markets, Biocon Biologics, said, 'Together, we hope to positively impact thousands of lives and strengthen Malaysia's efforts to deliver inclusive, patient-centric healthcare.'
Biocon Biologics aims to build on its previous success in expanding access to diabetes care in Malaysia, having served over 345,000 patients, and is now focusing on oncology through strategic partnerships like this.
Related
